Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in the world. Resistance to cytotoxic chemotherapy is a major cause of mortality in patients with HNSCC. A small subset of cancer cells called cancer stem cells (CSCs) may be key contributors to drug resistance and tumor recurrence in HNSCC. The aim of this study was to determine whether CD133, which maintains properties of CSCs, promotes chemoresistance by arresting cell cycle transition and reducing apoptosis in HNSCC cells. CD133 overexpression was examined in KB cells, and colony forming and aldehyde dehydrogenase activity assays were performed. To investigate the role of CD133 in chemoresistance, cell death was analyzed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), Diff-Quick, flow cytometry, and western blot of apoptosis-related protein expression in fluorouracil (5-FU)-or cisplatin-treated cells. In addition, microarray and related protein expression assessments were performed to investigate the mechanism of chemoresistance against 5-FU and cisplatin in KB cells. Moreover, chemoresistance against 5-FU or cisplatin in a KB-inoculated mouse model was analyzed by hematoxylin and eosin staining, immunohistochemical study of CD133, and immunofluorescence of tumor tissue. In this study, we demonstrate that ectopic overexpression of CD133 significantly promotes properties of stemness in KB cell lines. Furthermore, CD133 promotes chemoresistance by arresting transition of the cell cycle and reducing apoptosis, which results in inhibition of tumor growth in 5-FU-or cisplatin-injected mouse tumor model. Taken together, our findings show that elevated levels of CD133 lead to HNSCC chemoresistance through increased stemness and cell cycle arrest.
Introduction
Head and neck squamous cell carcinoma (HNSCC) develops in the upper aerodigestive tract, including the oral or nasal cavity, the pharynx, and the larynx. HNSCC is the sixth most common cancer in the world and remains a major health problem globally with an estimated 500,000 new cases diagnosed yearly. 1, 2 Although effective therapeutic modalities such as surgery, radiation, chemotherapy, and therapeutic combinations of these approaches are used in the management of this disease, recurrent HNSCC is almost inevitable and becomes resistant to further therapies. Systemic chemotherapy, which was considered an adjuvant in the past, is currently the major approach for organ preservation strategies for HNSCC patients; it is often combined with definitive radiotherapy or induction treatments, and is no longer reserved for palliative purposes. 3 Recently, interest in the cancer stem cell (CSC) model has dramatically altered the current research focus on cancer treatment and drug development. 4 CSCs share many of the properties of their non-neoplastic counterparts. [5] [6] [7] In addition, CSCs are characterized by remarkable abilities such as extensive proliferation, self-renewal, invasion, development of distant metastasis, and drug resistance. 8, 9 To investigate CSC properties, such as tumor initiation and recurrence, many studies have examined methods for the isolation of CSCs from cancer specimens or cell lines, and identified a side population of cells and several protein markers specific to CSCs. 10, 11 These CSC markers include CD44, CD133, CD90, CD13, aldehyde dehydrogenase (ALDH), oval cell marker OV6, and epithelial cell adhesion molecule. [11] [12] [13] Classic chemotherapeutic agents are postulated to target differentiated cells, while CSCs appear immune to their toxicity. This research supports the premise of a significant overlap between signaling pathways involved in drug resistance and the self-renewal of cancer cells. However, the molecular mechanisms that underlie this phenomenon remain poorly explored.
CD133, which is known as prominin-1 (PROM1) and as AC133, was first described as a cell surface marker on early progenitor cells and hematopoietic stem cells. It has been used as a marker to identify CSCs derived from primary solid tumors. 14 CD133 is a five-domain transmembrane protein, composed of an N-terminal extracellular tail, two small cytoplasmic loops, two large extracellular loops containing seven potential glycosylation sites, and a short C-terminal intracellular tail that can be alternatively spliced or phosphorylated. 15, 16 Furthermore, CD133 expression is used as a prognostic marker of survival in squamous cell carcinoma (SCC) 17, 18 and is negatively correlated with survival prognosis of patients with HNSCC. In addition, AC133, which is a glycosylated epitope of CD133 initially associated with embryonic stem cells and a variety of somatic stem cells, was extensively described as a putative CSC marker in blood, brain, colon, prostate, lung, breast, liver, and skin cancers. [19] [20] [21] Other studies found that CD133 is linked to cell metabolism as a glucose-responsive gene in myotubes 22 as well as has a role in bioenergetic stress 23 and non-exposure to high oxygen tension in gliomas. However, the physiological role of CD133 in HNSCC chemoresistance has yet to be explored.
In this study, we investigated the role of CD133 in the induction of chemoresistance and CSC-like characteristics in HNSCC. To investigate this relationship, we used a KB HNSCC cell line ectopically expressing CD133 and treated it with the anti-cancer drugs, 5 fluorouracil (5-FU) or cisplatin. Our findings support the hypothesis that CD133 plays a pivotal role in chemoresistance in HNSCC by positively regulating expression of CSC-related genes, and provides a plausible mechanism for the development of chemoresistance in HNSCC.
Materials and methods

Cell culture and chemical reagents
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA). KB cells were purchased from the Korean Cell Line Bank (KCLB no. 10017, Seoul, Korea) and maintained in RPMI 1640 medium (Welgene, Daegu, Korea) supplemented with 10% heat-inactivated fetal bovine serum (Gibco BRL Life Technologies, Rockville, MD, USA) and a 10% antibiotic-antimycotic solution (Welgene) at 37°C in a 5% CO 2 humidified chamber. After seeding, used medium was replaced with fresh medium and adherent cells were allowed to reach approximately 70% confluence. Cells were then detached using trypsin-ethylenediaminetetraacetic acid (EDTA) (Gibco BRL) and re-plated (subcultured) in 6-well plates for each experiment.
Cloning of human CD133
HT29 colon cancer cells (KCLB no. 30038) were used as a source of CD133 protein. Cloning of CD133 was performed as described previously. 24 293T cells (KCLB, no. 21573) were used as a positive control to confirm the translated fusion product. Briefly, 293T cells were grown to near-confluence in a 60-mm dish, followed by transient transfection with either pcDNA3.1/NT-GFP or pcDNA3.1/ NT-GFPCD133 using 0.6 µL of the FuGENE HD transfection reagent (Promega, Madison, WI, USA) with 0.2 µg of plasmid. After 48 h, cells were gently washed with ice-cold phosphate-buffered saline (PBS; Welgene).
Establishment of stably transfected KB-GFP control cells and KB-GFPCD133 cells expressing the fusion protein
Stable cell lines overexpressing green fluorescent protein (GFP) or the CD133-GFP fusion protein were generated by transfecting confluent KB cells in 100-mm plates with 20 µg of pcDNA3.1/NT-GFPCD133 or pcDNA3.1/NT-GFP as described previously. 24 
Western blot
Once cell cultures were approximately 70% confluent, the medium was removed, cells were washed twice with PBS, and cell lysates were prepared in 200 µL of cold lysis buffer (1% NP-40, 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.02% sodium azide, 150 mg/mL phenylmethylsulfonyl fluoride (PMSF), 2 mg/mL aprotinin, 20 mg/mL leupeptin, and 1 mg/mL pepstatin A). Approximately 30 µg of protein from each sample was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% gel and transferred to a polyvinylidene difluoride membrane (Amersham, Piscataway, NJ, USA). The membrane was incubated for 0.5 h with a blocking solution consisting of 5% skim milk in Tris-buffered saline and Tween 20 (TBST: 2.42 g/L Tris-HCl, 8 g/L NaCl, 0.1% Tween 20, pH 7.6), rinsed briefly in TBST, and incubated overnight at 4°C with the appropriate primary antibody: anti-CD133 (1:500; MyBioSource, San Diego, CA, USA), anti-OCT4 (1:1000; Cell Signaling Technology, Danvers, MA, USA), anti-NANOG (1:1000; Cell Signaling Technology), anti-procaspase 3 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-procaspase 9 (1:1000; Santa Cruz Biotechnology), anti-BAX (1:1000; Santa Cruz Biotechnology), anti-BCL2 (1:1000; Santa Cruz Biotechnology), anti-cyclin E (1:1000; Santa Cruz Biotechnology), anti-cyclin A (1:1000; Santa Cruz Biotechnology), or anti-cyclin D (1:1000; Santa Cruz Biotechnology). Mouse monoclonal anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) IgG (1:2500; Santa Cruz Biotechnology) was used as a control. After rinsing with TBST, the membrane was incubated for 1 h with an anti-rabbit or anti-mouse horseradish peroxidase-conjugated secondary antibody (1:2000; Santa Cruz Biotechnology). Finally, the membrane was washed in TBST, and protein immunoreactivity was detected using an enhanced chemiluminescence detection kit (Amersham). Protein levels were determined by densitometry analysis using the ImageJ software (rsb.info.nih.gov/ij).
Confocal microscopic analyses
Cells were counterstained using 4′,6-diamidino-2phenylindole (DAPI) in ProLong Gold antifade mounting medium (Invitrogen, Carlsbad, CA, USA) to visualize nuclear morphology. Digital images were captured using a TCS SP5 AOBS laser-scanning confocal microscope (Leica Microsystems, Heidelberg, Germany) with a 20× objective at the Korea Basic Science Institute Gwangju Center at Gwangju, Korea.
Colony forming assay
Non-adherent 24-well culture plates were coated with a 10% polyHEMA (Sigma-Aldrich) solution in absolute ethanol and dried overnight. After seeding, cells were incubated in serum-free Dulbecco's modified Eagle's Medium (DMEM; Welgene) supplemented with 200 ng/ mL epithelial cell growth factor (R&D systems, Minneapolis, MN, USA), 20 ng/mL basic fibroblast growth factor (Sigma-Aldrich), and B-27 supplement (Invitrogen). After an incubation of 5 days, the number of spheroids in each well was counted under a light microscope (Zeiss, Zena, Germany).
Flow cytometry assessment of ALDH activity
Flow cytometry was used to examine tumor-derived cells using the ALDEFLUOR kit (StemCell Technologies, Vancouver, Canada). Cells were suspended in ALDEFLUOR assay buffer containing ALDH1 substrate (BODIPY-aminoacetaldehyde; 1 M per 10 6 cells) and incubated for 30 min at 37°C. Some cell batches were incubated with the specific ALDH1 inhibitor diethylaminobenzaldehyde (DEAB; 50 mM) and were used as negative controls. Cells were washed twice with washing buffer and analyzed by flow cytometry (FC-500, Beckman Coulter, Carlsbad, CA, USA). Approximately 10,000 counts were accumulated for each sample.
Cell viability assay
Cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) assay. Cells were seeded at 5 × 10 3 in 200 µL of medium in 96-well plates and cultured for 1 day at 37°C. After each experiment, medium was removed and 20 µL MTT (50 µg/mL) was added to each well. Cells were incubated at 37°C for 4.5 h to allow color formation, and the formazan product was solubilized by addition of 50 µL dimethyl sulfoxide (Calbiochem Bio-Mol, La Jolla, CA, USA). Optical density at 570 nm was measured using a microtiter plate reader (Bio-Rad, Hercules, CA, USA).
Histomorphological evaluation (Diff-Quick staining)
To analyze morphological changes, cells were stained using the Diff-Quick method (International Reagents Corp., Kobe, Japan). Diff-Quick staining was originally designed to incorporate cytoplasmic staining (pink) with nuclear staining (blue) for rapid cytological detection. Cells (1 × 10 6 ) were seeded on coverslips with 2 mL of medium in 6-well plates. Following 24 h incubation, the coverslips were allowed to air dry for 10 min. Next, the coverslips were treated with Diff-Quick fixative for 60 s, Diff-Quick Solution I for 60 s, and Diff-Quick Solution II for 60 s, washed in deionized water for 10 s, allowed to air dry, mounted on slides, and examined by light microscopy.
Flow cytometry analysis of apoptosis
Cells in early and late apoptotic stages were quantified using an Annexin V-FITC/PI double staining assay. Cells were harvested with trypsinization and washed twice with PBS. Cells were resuspended in 500 µL binding buffer, followed by staining with 10 µL Annexin V and 5 µL propidium iodide (PI) in the dark at room temperature (RT) for 15 min. Stained cells were immediately examined using a FACS flow cytometry analyzer (Beckman Coulter) with wavelength emission filters of 488-530 nm for the green fluorescence of Annexin V (FL1) and of 488-630 nm for the red fluorescence of PI (FL2). At least 10,000 cells per sample were acquired to ensure sufficient data collection.
Gene expression analysis using microarrays
For RNAs of KB Vec or KB CD133+ , the synthesis of target complementary RNA (cRNA) probes and hybridization were performed using Agilent's LowInput QuickAmp Labeling Kit (Agilent Technology, Santa Clara, CA, USA) according to the manufacturer's instructions. Briefly, 25 ng of both total RNA and T7 promoter primer were mixed and incubated at 65°C for 10 min. The cDNA master mix (5X First strand buffer, 0.1M DTT, 10 mM dNTP mix, RNase-Out, and MMLV-RT) was prepared and added to the reaction. Samples were incubated at 40°C for 2 h followed by reverse transcription polymerase chain reaction (RT-PCR), and double stranded DNA (dsDNA) synthesis was terminated by incubating at 70 C for 10 min. The transcription master mix was prepared using the manufacturer's protocol (4X transcription buffer, 0.1M DTT, dNTP mix, 50% polyethylene glycol (PEG), RNase-Out, Inorganic pyrophosphatase, T7-RNA polymerase, and Cyanine 3/5-CTP). Transcription of dsDNA was performed by adding the transcription master mix to the dsDNA reaction samples and incubating at 40°C for 2 h. Amplified and labeled cRNA was purified using RNase mini columns (Qiagen, Alameda, CA, USA) according to the manufacturer's protocol. The labeled cRNA target was quantified using a ND-1000 spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE, USA). After checking labeling efficiency, 850 ng of both cyanine 3-labeled and cyanine 5-labeled cRNA targets were mixed, and cRNA fragmentation was performed by adding 10X blocking agent and 25X fragmentation buffer, followed by incubation at 60 C for 30 min. The fragmented cRNA was resuspended using 2X hybridization buffer and directly pipetted onto an assembled Agilent Human GE 4X 44K v2 Microarray. The arrays were hybridized at 65°C for 17 h using an Agilent Hybridization oven (Agilent Technology). Hybridized microarrays were washed using the manufacturer's washing protocol (Agilent Technology).
Data acquisition and analysis
The hybridization images were scanned using an Agilent DNA microarray Scanner (Agilent Technology), and data quantification was performed using Agilent Feature Extraction software 10.7 (Agilent Technology). The average fluorescence intensity for each probe was calculated, and local background was subtracted. All data normalization and identification of fold-changed genes were performed using GeneSpringGX 7.3.1 (Agilent Technology). Genes were filtered with removing flag-out genes in each experiment. Intensity-dependent normalization (locally weighted scatterplot smoothing (LOWESS)) was performed, where the ratio was reduced to the residual of the LOWESS fit of the intensity versus the ratio curve. The averages of normalized ratios were calculated by dividing the average of the normalized signal channel intensity by the average of the normalized control channel intensity. Functional annotation of genes was performed according to the Gene Ontology TM Consortium (www.geneontology. org/index.shtml) using GeneSpring GX 7.3.1.
Flow cytometry analysis of cell cycle
Cells were trypsinized to obtain a single-cell suspension, harvested by centrifugation, and washed with PBS. After fixation in ice-cold 70% ethanol at 4°C overnight, cells were collected and washed twice with PBS. The cells were then stained with PI (3 µg/mL) for 15 min. Afterwards, DNA from 10 4 of G0/S phase cells was quantified using a flow cytometer (Beckman Coulter).
Animal experiments
Five week-old male athymic nude mice (BL-6/nu, Orient Bio Co. LTD, Seoul, Korea) were housed under controlled light conditions and fed ad libitum. Xenograft tumors were generated by injecting KB Vec or KB CD133+ into the flanks of mice and treated with either saline, 5-FU, or cisplatin. 25 The animal protocol was approved by the Institutional Animal Care and Use Committee, Chosun University, Gwangju, Korea (CIACUC2016-S0007).
Following treatment, mice were sacrificed by intraperitoneal administration of 0.4% sodium pentobarbital (1 mL/ kg). All tumor samples were dissected and tumor weights were measured. Afterwards, all tumor samples were fixed in 10% buffered formalin (Merck, Darmstadt, Germany), embedded in paraffin, sectioned, and mounted without staining for monitoring of GFP immunofluorescence or stained with hematoxylin and eosin (H&E; Merck) for histological analysis.
Immunohistochemical study
Three micrometer-thick sections were deparaffinized in three changes of xylene and rehydrated in a graded series of ethanol to distilled water. For antigen retrieval, slides were placed in 0.01 M citrate-buffer pH 6.0 and heated in a steamer for 30 min. Endogenous peroxidases quenching was done by the slides incubating in 3% hydrogen peroxide for 20 min at RT. Sections were incubated overnight at 4°C with a 1:50 dilution primary antibody: mouse polyclonal anti-CD133 (Mybiosource, San Diego, CA). Subsequently, sections were incubated with biotinylated secondary antibody (LSAB; Dako Cytomation, Glostrup, Denmark) for 30 min, washed in PBS, and incubated with streptavidin-peroxidase conjugate (LSAB, Dako Cytomation) for 30 min. The reaction was developed using 3,30-diaminobenzidine tetrahydrocloride (Sigma-Aldrich) for 5 min. Slides were briefly counterstained in hematoxylin, dehydrated, and cover slipped. Negative and positive controls were run simultaneously. Positive controls were represented by mammary tissue.
Statistical analysis
All analyses were performed using GraphPad Prism Ver. 6.0 (GraphPad Software Inc. San Diego, CA, USA). All data were expressed as mean ± standard error of the mean (SEM) with statistical significance considered with p < 0.05. Statistical comparisons between control and treatment groups were determined using an unpaired t test or a oneway analysis of variance (ANOVA) with Tukey's post-hoc test.
Results
Stable overexpression of CD133 in KB cells
To determine the effect of CD133 overexpression in vitro, we established stable cell lines overexpressing CD133 under the control of a constitutive promoter. Specifically, we transfected the HNSCC KB cell line with either GFP-tagged CD133 or an empty vector simply containing GFP. A representative CD133-GFP clone was selected from KB CD133+ and compared with a control cell line transfected with plasmid expressing GFP alone (KB Vec ). Transiently transfected 293T cells with GFP (293T Vec ) or CD133-GFP (293T CD133+ ) were used as positive controls. At the protein level, basal expression of CD133 was very low in KB Vec , but significantly higher in the stable CD133-GFP-transfected cells (KB CD133+ ) and transiently transfected 293T cells (Figure 1(a) ). KB CD133+ cells expressed green fluorescence in the cytosol and cell membrane (Figure 1(b) ).
Stem cell properties in KB cells following ectopic overexpression of CD133
To examine the role of CD133 in cancer stemness, we analyzed cells for CSC-like properties (i.e. increased ability to form tumor spheres, ALDH activity, and expression of stem cell-like markers such as ALDHA1, OCT4, and NANOG). We found that KB CD133+ cells had increased expression of OCT4, ALDHA1, and NANOG, consistent with increased stemness (Figure 2(a) ). In addition, stemness was confirmed using the colony formation assay. KB CD133+ cells were significantly better at forming colonies than that found in control cells (Figure 2(b) ). Next, using the ALDEFLUOR assay, we assessed ALDH activity in KB CD133+ cells (Figure 2(c) ), and found that 1.84% of KB Vec cells were ALDEFLUOR-positive. In contrast, we found that 5.3% of KB CD133+ cells were ALDEFLUOR-positive. These results demonstrate that ectopic overexpression of CD133 in KB cells results in increase of ALDH activity, colony forming ability, and expression of ALDHA1, OCT4, and NANOG.
Effects on apoptotic cell death by 5-FU or cisplatin treatment in CD133-overexpressing KB cells
To determine whether ectopic overexpression of CD133 decreased the efficacy of 5-FU or cisplatin, we measured the cytotoxicity of both drugs at various concentrations with a 24 h exposure in KB Vec and KB CD133+ cells. We found that cell viability of KB CD133+ cells was higher than that found in KB Vec cells during the entire incubation period (Figure 3(a) ), with an LD 50 of 0.6 mM and 0.8 mM for 5-FU and cisplatin, respectively, in KB Vec cells. These LD 50 concentrations were used in follow-up experiments.
To evaluate the effects of 5-FU or cisplatin on cytotoxicity of KB Vec and KB CD133+ cells over time, treatment using 0.6 mM of 5-FU or 0.8 mM cisplatin for 0, 3, 6, 12, and 24 h were performed in KB Vec and KB CD133+ (Figure 3(b) ). KB Vec cells treated with 5-FU or cisplatin for 0, 3, 6, 12, and 24 h showed a time-dependent decrease in cell viability. Of importance, we found no significant cytotoxicity in KB CD133+ cells using 5-FU.
The morphological features of KB Vec and KB CD133+ cells treated with 0.6 mM of 5-FU or 0.8 mM of cisplatin at 24 h were observed to determine whether the anti-cancer drugs induced morphological changes associated with apoptosis ( Figure 3(c) ). KB Vec cells treated with either 5-FU or cisplatin showed a reduced number of cells compared to that found in KB CD133+ cells. Furthermore, KB CD133+ cells displayed intact cellular morphologies, but 5-FU-or cisplatin-treated KB Vec cells showed evidence of apoptosis (i.e. apoptotic bodies with membrane blebs characteristic of apoptotic cell death).
Using flow cytometry analysis with an Annexin V-FITC/PI double staining assay, we evaluated 5-FU-or cisplatin-induced apoptotic cell death in KB Vec and KB CD133+ cells (Figure 3(d) ), and found that the B2 region, which represents a late stage of apoptotic cells, was increased from 2.4% to 2.9% in 5-FU-induced and 17.3% in cisplatin-induced KB Vec cells. However, we found that the B2 region in KB CD133+ cells was lower being 1.9% in 5-FU-induced and 9.4% in cisplatin-induced KB CD133+ cells compared to that found in KB Vec cells. We further characterized changes to key proteins involved in the apoptotic pathway. Using western blot analysis, we found that the levels of pro-caspase 3 to caspase 3 in KB Vec cells were significantly increased by 5-FU or cisplatin treatment in a time-dependent manner (Figure 3(e) and (f) ). However, we found there were no changes from pro-caspase 3 to caspase 3 in 5-FU treated KB CD133+ cells. In addition, expression of the anti-apoptotic protein Bcl-2 (also known as BCL2) in KB Vec cells was significantly inhibited by 5-FU as well as by cisplatin compared to that found in KB CD133+ cells. Expression of another important apoptotic protein, BAX, was also significantly increased by 5-FU or cisplatin treatment in KB Vec cells, but was decreased in KB CD133+ cells. Our findings of reduced Bcl-2 expression in addition to increased expression of BAX and caspase 3 activation in KB CD133+ cells by 5-FU treatment particularly indicate that CD133 overexpression drives cells to undergo apoptosis and develop chemoresistance to 5-FU.
Effects on cell cycle arrest in CD133overexpressing KB cells
Using GeneSpringGX software, differentially expressed genes with a functional annotation were identified in both KB Vec and KB CD133+ cells (Figure 4 cell cycle-related genes were significantly upregulated. Therefore, to investigate the effect on resistance against cancer drugs, cell cycle checkpoint-related genes that are differentially expressed because of CD133+ overexpression in KB cells were identified. The differentially expressed genes with a fold-change >2 in KB CD133+ cells compared to that found in KB Vec control cells were RPS27L, CCNE2, CCNA2, CCND1, and CENPF. Their relative mRNA expression levels were significantly downregulated in KB CD133+ cells compared to that found in KB Vec cells (Figure 4(c) ), a finding that indicates cell cycle checkpoint-related genes were downregulated because of ectopic overexpression of CD133 in KB cells. Therefore, we investigated protein expression related to cell cycle checkpoints with 5-FU or cisplatin treatment in KB Vec and KB CD133+ cells (Figure 4(d) ). We found that expression of p53, which has a crucial role in the cell cycle checkpoint in KB Vec cells, was decreased compared to that found in KB CD133+ cells. However, treatment with either 5-FU or cisplatin led to significantly increased p53 expression in KB Vec cells. In addition, expression of cyclin E, which advances the cell cycle, was increased in KB Vec cells compared to that found in KB CD133+ cells, but 24 h treatment with either 5-FU or cisplatin resulted in a significant decrease in its expression in KB Vec cells.
To determine whether the cell cycle pattern changed because of CD133 overexpression in KB cells, we performed flow cytometry analysis in KB Vec and KB CD133+ cells (Figure 4(e) ). We found that in KB Vec cells, the G0/G1 stage was 58.1%, S stage was 28.6%, and the G2/M stage was 14.3%. However, we found that G0/G1 was 84.8%, the S stage was 12.6%, and the G2/M stage was 0.9% in KB CD133+ cells. Taken together, overexpression of CD133 in KB cells results in cell cycle arrest that in turn induces development of chemoresistance against 5-FU or cisplatin.
Histological findings and distribution of CD133-overexpressing KB cells
Finally, to determine whether overexpression of CD133+ increases chemoresistance in a xenograft model, treatment using 5-FU or cisplatin was performed in KB Vec or KB CD133+ cells inoculated in mice, and tumor growths were measured ( Figure 5(a) ). Treatment using either 5-FU or cisplatin significantly decreased both tumor growth and weight in KB Vec -inoculated mice (Figure 5(b) and (c)). However, treatment using either 5-FU or cisplatin did not lead to decreased tumor growth or weight in KB CD133+inoculated mice. Furthermore, H&E staining showed that inoculation of KB CD133+ cells in mice exhibited blood vessels and necrotic lesion similar to that found in KB Vecinoculated mice ( Figure 5(d) ). However, 5-FU or cisplatin treatment did not decrease tumor lesion in KB CD133+inoculated mice compared to that found using KB Vec cells, a finding that indicates KB CD133+ cells have an increased resistance against 5-FU and cisplatin. In addition, we found GFP-fluorescence and immunoexpression of CD133 in KB CD133 cells in 5-FU-or cisplatin-treated mice compared to that seen in KB Vec cells (Figure 5 (e) and (f)). Taken together, CD133 overexpression results in decreased tumor degeneration by 5-FU or cisplatin treatment in a mouse model.
Discussion
HNSCC is difficult to treat clinically and is resistant to conventional chemotherapy and radiation treatment modalities. 26 Although 5-year survival rates of HNSCC are high even at an advanced stage, the prognosis of HNSCC remains poor because many cases of HNSCC eventually become chemotherapy-resistant in addition to recurrence and development of metastasis. Current conventional treatments of HNSCC eliminate most cells within a tumor, but advanced cancers still progress to an incurable and metastatic disease state. 27 Nowadays, many studies have proposed that CSCs may be a major cause of therapy resistance in advanced HNSCC. These small populations of cells possess unlimited self-renewal capacities and can regenerate tumorigenic progenies, and therefore, have an essential role in HNSCC therapy resistance, metastasis, and disease relapse. 28 Therefore, targeting these CSCs may be a promising and effective strategy to combat HNSCC. To investigate the resistance of conventional anti-cancer drugs, we first sought to identify CSC-like cells by inducing ectopic overexpression of CD133 in the HNSCC KB cell line. Acquisition of the capacity for self-renewal and stemness is essential for tumorigenesis, and for continued accumulation of oncogenic changes that lead to cancer. 24 Overexpression of CD133 in KB cells leads to expression of several factors related to stemness, including expression of OCT4, ALDHA1, and NANOG, which provide cells with colony forming abilities and ALDH activity. Our findings confirmed that HNSCC cells had potentiated stem cell features because of CD133. Overexpression of CD133 in HNSCC cells facilitated both in vitro self-renewal of HNSCC cells and in vivo xenograft growth.
The results of the present study that demonstrate CD133 expression increases resistance of KB cells to chemotherapeutic reagents such as 5-FU and cisplatin strongly suggest the necessity for the implementation of therapeutic regimens that consider CD133 as a priority target. Especially, 5-FU treatment using higher doses over 0.6 mM could not effectively cause cell death in KB CD133+ cells compared to that found in KB Vec cells. In contrast to KB CD133+ cells, treatment with 5-FU of KB Vec cells led to the induction of apoptosis via upregulation of BAX and downregulation of Bcl-2, and finally, caspase 3 activation. Oligomerization of BAX results in the formation of pores in the outer mitochondrial membrane, which promotes the release of cytochrome c, whereas Bcl-2 binds to BAX and inhibits the formation of BAX oligomers. 29 Thus, increasing the level of Bcl-2 relative to BAX (i.e. a lower BAX/Bcl-2 ratio) promotes the mitochondrial retention of cytochrome c and results in the reduced apoptotic cell death observed in KB CD133+ cells. These results indicate that CD133 overexpression in HNSCCs leads to inhibition of anti-cancer drug-induced apoptosis, especially 5-FU, resulting in the onset of chemoresistance.
Next, we asked how CD133 promotes reduction of apoptosis in anti-cancer drugs used to treat HNSCC. To answer that question, we performed microarray analysis in KB Vec and KB CD133+ cells. We found by microarray data analysis that many genes and pathways are involved in 5-FU or cisplatin resistance, which highlights the complexity of chemoresistance mechanisms, as demonstrated both by our findings and that of others made previously. [30] [31] [32] We found that 16% of cell cycle-related genes were upregulated because of CD133 overexpression, whereas genes associated with cell cycle checkpoints such as RPS27L, CCNE2, CCNA2, and CCND1 were significantly decreased. We also found that because of CD133 overexpression, p53 protein expression was significantly increased while cyclin E expression was decreased, which resulted in decreased S and G2/M stages. CSCs are quiescent cells, and since most conventional chemotherapeutic drugs interfere with the growth of rapidly dividing cancer cells, it is believed that CSCs are spared from these treatments. Consequently, this leads to chemoresistance, metastasis, and tumor recurrence. We reported for the first time the cell cycle status of KB Vec and KB CD133+ cells. Our findings clearly show that KB CD133+ cells were quiescent compared to that found in KB Vec cells. Furthermore, this observation is in agreement with existing stem cell theory, further demonstrating the slow-cycling nature of stem cells.
In HNSCC, cisplatin and 5-FU treatment is an accepted induction chemotherapy regimen. 33 Multiple studies have reported the anti-tumor effects of 5-FU or cisplatin in treating head and neck cancer. 5-FU was the systemic agent of choice for advanced HNSCC for many years, and several recent studies have demonstrated a valuable role for 5-FU in treatment protocols. Also, cisplatin, which is a platinum-based chemotherapeutic agent, is currently the backbone for several chemotherapy combinations used in treating metastatic and locally recurring HNSCC as well as other cancers. 34 In this study, we have shown that KB Vec and KB CD133+ cells exposed to either 5-FU or cisplatin developed resistance and acquired protein expression, including decreased p53 and increased cyclin E. Furthermore, CD133+ cells treated with 5-FU or cisplatin acquired cell cycle progression-related protein expression, which resulted in survival in 5-FU-or cisplatin-treated mice. The mechanism of 5-FU has been associated with inhibition of thymidylate synthase (TS) and the incorporation of 5-FU into RNA and DNA, 35 which results in the cytotoxic action. Evidence that this mechanism contributes to toxicity was obtained from studies with uridine protection. In normal epithelium of the intestine, p53-dependent apoptosis was only inhibited by uridine, and not by thymidine, after exposure to 5-FU. 36 In addition, the cytotoxic effects of cisplatin largely depend on the activation of apoptosis. Cisplatin exerts anti-cancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions, followed by the activation of the DNA damage response, and the induction of mitochondrial apoptosis. 37 Prolonged arrest of cell division eventually activates a checkpoint and induces programmed cell death. The mechanism that is relevant to cisplatin resistance involves overexpression of the copper transporter CTR1 (also known as SLC31A1), which is a major influx transporter, and resulting modulation of p53 activities. 38 Therefore, in the present study, CD133 overexpression led to cell cycle arrest in KB cells and induced chemoresistance to anti-cancer drugs, especially 5-FU. Although many current therapeutic strategies target a specific self-renewal pathway using a unique drug/inhibitor, such compounds are unlikely to be effective considering the involvement of multiple interactive pathways that drive self-renewal capacity in CSCs. Hence, targeting one specific pathway will allow cancer cells to "escape" via alternative pathways, and thus, such approaches will be inadequate to eliminate CSCs.
In summary, our findings show that CD133 has a functional role in regulating stem cell properties in HNSCCs by promoting colony formation, ALDH activity, and increased expression of CSC markers such as OCT4 and NANOG. In addition, CD133 overexpression leads to increased gene expression related to the cell cycle checkpoint and induced cell cycle arrest that results in induction of anti-apoptosis in 5-FU-or cisplatin-treated HNSCC cells and inhibition of tumor growth in 5-FU-or cisplatininoculated mouse models. Our data substantiate the role of chemoresistance and that of CSCs in HNSCC. Therefore, our results may facilitate the development of a novel classification system and therapeutic strategies for HNSCC.
